[go: up one dir, main page]

WO2003062379A3 - Molecules for disease detection and treatment - Google Patents

Molecules for disease detection and treatment Download PDF

Info

Publication number
WO2003062379A3
WO2003062379A3 PCT/US2003/001363 US0301363W WO03062379A3 WO 2003062379 A3 WO2003062379 A3 WO 2003062379A3 US 0301363 W US0301363 W US 0301363W WO 03062379 A3 WO03062379 A3 WO 03062379A3
Authority
WO
WIPO (PCT)
Prior art keywords
mddt
provides
disease detection
treatment
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/001363
Other languages
French (fr)
Other versions
WO2003062379A2 (en
Inventor
Anissa L Jones
Christopher R Dahl
Darryl Gietzen
Joyce Chinn
Gerard E Dufour
Jennifer L Jackson
Jimmy Y Yu
Olivia Tuason
Pierre E Yap
Stefan R Amshey
Tam C Dam
Tommy F Liu
Edward H Gerstin Jr
Careyna H Peralta
Samantha A Lewis
Alice J Chen
Rakesh Marwaha
Ruth Y Lan
Michael E Urashka
Sreenivasa R Kristnam
Vijaykumar Kolluru
Iqbal S Panesar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to AU2003205174A priority Critical patent/AU2003205174A1/en
Publication of WO2003062379A2 publication Critical patent/WO2003062379A2/en
Publication of WO2003062379A3 publication Critical patent/WO2003062379A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides purified disease detection and treatment molecule polynucleotides (mddt). Also encompassed are the polypeptides (MDDT) encoded by mddt. The invention also provides for the use of mddt, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing mddt for the expression of MDDT. The invention additionally provides for the use of isolated and purified MDDT to induce antibodies and to screen libraries of compounds and the use of anti-MDDT antibodies in diagnostic assays. Also provided are microarrays containing mddt and methods of use.
PCT/US2003/001363 2002-01-17 2003-01-14 Molecules for disease detection and treatment Ceased WO2003062379A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003205174A AU2003205174A1 (en) 2002-01-17 2003-01-14 Molecules for disease detection and treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34941302P 2002-01-17 2002-01-17
US34994602P 2002-01-17 2002-01-17
US60/349,946 2002-01-17
US60/349,413 2002-01-17

Publications (2)

Publication Number Publication Date
WO2003062379A2 WO2003062379A2 (en) 2003-07-31
WO2003062379A3 true WO2003062379A3 (en) 2004-02-19

Family

ID=27616740

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/001363 Ceased WO2003062379A2 (en) 2002-01-17 2003-01-14 Molecules for disease detection and treatment
PCT/US2003/001605 Ceased WO2003062385A2 (en) 2002-01-17 2003-01-15 Secretory molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/001605 Ceased WO2003062385A2 (en) 2002-01-17 2003-01-15 Secretory molecules

Country Status (2)

Country Link
AU (2) AU2003205174A1 (en)
WO (2) WO2003062379A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641922B1 (en) * 2003-07-07 2012-09-26 Universiteit Utrecht Holding B.V. Newly identified cholinephosphotransferases and ethanolaminephosphotransferases
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 substituted nucleotide analogs
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033401A2 (en) * 1999-02-26 2000-09-06 Genset Expressed sequence tags and encoded human proteins
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993827A (en) * 1993-09-10 1999-11-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
US6277977B1 (en) * 1997-06-11 2001-08-21 Smithkline Beecham Corporation cDNA clone HAPOI67 that encodes a human 7-transmembrane receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033401A2 (en) * 1999-02-26 2000-09-06 Genset Expressed sequence tags and encoded human proteins
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Also Published As

Publication number Publication date
WO2003062385A3 (en) 2006-09-08
WO2003062385A2 (en) 2003-07-31
AU2003236612A8 (en) 2006-11-09
WO2003062379A2 (en) 2003-07-31
AU2003205174A1 (en) 2003-09-02
AU2003236612A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2002079449A3 (en) Molecules for disease detection and treatment
WO2004023973A3 (en) Molecules for diagnostics and therapeutics
WO2000073509A3 (en) Molecules for diagnostics and therapeutics
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2002083876A3 (en) Secretory molecules
WO2003000842A3 (en) Novel proteins and nucleic acids encoding same
Szantai-Kis et al. Thieme Chemistry Journals Awardees–Where Are They Now? Improved Fmoc Deprotection Methods for the Synthesis of Thioamide-Containing Peptides and Proteins
WO2000078968A3 (en) Nucleotide sequences of moraxella catarrhalis genome
WO2007054520A3 (en) Methods for the identification of microrna and their applications in research and human health
WO2003093316A3 (en) Immunoglobulin-domain containing cell surface recognition molecules
WO2002040715A3 (en) Molecules for disease detection and treatment
WO2003062376A3 (en) Molecules for diagnostics and therapeutics
WO2002020756A3 (en) Secretory molecules
WO2003062379A3 (en) Molecules for disease detection and treatment
WO2001062922A3 (en) Polypeptides and corresponding molecules for disease detection and treatment
WO2002055738A3 (en) Molecules for disease detection and treatment
WO2003040325A3 (en) Novel proteins and nucleic acids encoding same
EA200501197A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALIGNANT TUMOR USING IGSF9 AND LIV - 1
WO2001062927A3 (en) Polypeptides and corresponding polynucleotides for diagnostics and therapeutics
WO2000075298A3 (en) Molecules for disease detection and treatment
WO2002020754A3 (en) Molecules for diagnostics and therapeutics
WO2001062918A3 (en) Secretory polypeptides and corresponding polynucleotides
WO2002079473A3 (en) Molecules for diagnostics and therapeutics
WO2001023538A3 (en) Molecules for disease detection and treatment
WO2003083046A3 (en) Novel proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR HU IE IT LU MC NL PT SE SI TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP